At Ultragenyx, we fundamentally believe that taking real impactful action to care for the needs of patients and our people is always the right thing to do. To achieve this goal, our vision is to lead the future of rare disease medicine. For us, this means going where other biopharma companies won’t go – challenging the status quo and creating a new model that advances our field so more patients and caregivers can benefit from life-changing treatments. We do this by following the science, applying a novel rapid development approach, making innovative medicines at fair and reasonable prices, and creating a collaborative ecosystem to reach patients in ways that are most meaningful for them.
Our commitment and care for patients extends to our people, so culture is an essential cornerstone for Ultragenyx. We remain continuously focused on creating a supportive and inclusive environment of profound learning and growth – so employees can thrive in all areas of their lives, in and outside of work. Ultimately, we want to be an organization where we would be proud for our family, friends and children to work.
If you want to have a meaningful impact, do the best work of your career, and grow a lot, both professionally and personally, come join our team. During the COVID-19 Outbreak, we are committed to our hiring process. The health and safety of our employees and prospective employees take priority which means at this time our approach will include video discussions, interviews, and onboarding.
Location: United States, California, Novato
Employees: 501-1000
Total raised: $45M
Founded date: 2010
Investors 5
Date | Name | Website |
- | F-Prime Ca... | fprimecapi... |
- | RA Capital... | racap.com |
23.05.2022 | Internatio... | ibtplc.com |
- | TPG | tpg.com |
- | Eight Road... | eightroads... |
Funding Rounds 1
Date | Series | Amount | Investors |
20.06.2011 | Series A | $45M | - |
Mentions in press and media 37
Date | Title | Description | Source |
05.06.2023 | Ultragenyx and Mereo BioPharma Announce Positive Data from t... | /EIN News/ -- Pediatric data show substantial induction of bone production in 1 week and a large inc... | einpresswi... |
06.01.2023 | Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 20... | Preliminary 2022 Total Product Revenue of $352 million to $356 million, Crysvita® Revenue in Ultrage... | einpresswi... |
09.09.2022 | Ultragenyx and Mereo BioPharma to Present Setrusumab Data Up... | NOVATO, Calif. and MOUNTAIN VIEW, Calif. and LONDON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx P... | globenewsw... |
11.02.2022 | Ultragenyx Reports Fourth Quarter and Full Year 2021 Financi... | 2021 total revenue of $351.4 million and 2021 Crysvita® revenue in Ultragenyx territories1 of $192.6... | marketscre... |
11.02.2022 | Ultragenyx Pharmaceutical : Reports Fourth Quarter and Full ... | Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update 2021 to... | marketscre... |
05.01.2022 | GeneTx and Ultragenyx Provide Preliminary Update on Phase 1/... | SARASOTA, Fla. and NOVATO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and ... | marketscre... |
01.12.2021 | Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinic... | NOVATO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a b... | marketscre... |
02.11.2021 | Ultragenyx Reports Third Quarter 2021 Financial Results and ... | Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate Update Third quarter 2021 tot... | marketscre... |
02.11.2021 | Ultragenyx Reports Third Quarter 2021 Financial Results and ... | Third quarter 2021 total revenue of $81.6 million including Crysvita1 revenue to Ultragenyx of $50.3... | marketscre... |
09.09.2021 | MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase... | NOVATO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutic... | marketscre... |
Show more